Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Immunome director buys $27k in company stock

Published 23/05/2024, 06:54 am
IMNM
-

In a recent transaction, Jean Jacques Bienaime, a director at Immunome Inc. (NASDAQ:IMNM), purchased shares of the company's common stock, signaling a vote of confidence in the pharmaceutical firm. The transaction, which took place on May 21, involved the acquisition of 2,000 shares at a price of $13.57 per share, totaling approximately $27,139.

This purchase increases Bienaime's total holdings in Immunome to 9,615 shares, according to the latest filings. Investors often look to insider buying as a positive sign that company executives and directors believe in the company's future prospects.

Immunome Inc., known for its focus on pharmaceutical preparations, is watched closely by market participants who track insider transactions for insights into the company's performance and strategic direction.

Investors and market observers will continue to monitor insider activity at Immunome as it can provide valuable context to the company's financial health and executive sentiment.

InvestingPro Insights

Following the insider share purchase by Director Jean Jacques Bienaime at Immunome Inc. (NASDAQ:IMNM), the market is keenly observing the company's financial metrics and performance indicators. According to InvestingPro data, Immunome has a market capitalization of approximately $864.38 million and has experienced a significant 167.65% one-year price total return as of the latest data, showcasing a robust performance in the stock market over the past year.

Two notable InvestingPro Tips for Immunome Inc. suggest that the company holds more cash than debt on its balance sheet and that the stock has recently been in oversold territory according to the Relative Strength Index (RSI). This combination of financial stability and potential market undervaluation could be factors contributing to Bienaime's decision to increase his stake in the company.

Moreover, despite a challenging gross profit margin of -80.75% over the last twelve months as of Q1 2024, Immunome's liquid assets exceed its short-term obligations, which may provide a cushion against near-term financial pressures. Additionally, while the company does not pay a dividend, the significant return over the last year could be a point of interest for investors seeking capital appreciation.

For those looking to delve deeper into Immunome's financials and stock performance, InvestingPro offers a comprehensive suite of tools and additional tips. There are currently 11 more InvestingPro Tips available for IMNM, which can be accessed by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.